Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

Relapsed Small Cell Lung Cancer Clinical Trial

Official title:
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors

Status Completed

Clinical Trial Summary

A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients

Clinical Trial Description

This is a dose-escalation study of Low-dose Radiation in combination with CS1001 in relapsed SCLC patients. Patients are assigned to 3 treatment groups received from 3 Gy to 15Gy, to determine the safety, tolerability and the maximal tolerant dose. Biomarkers and immunological markers are collected and analyzed as well. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04421352
Study type	Interventional
Source	CStone Pharmaceuticals
Contact
Status	Completed
Phase	Phase 1
Start date	January 12, 2021
Completion date	December 22, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04610658` - Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC	Phase 1
Recruiting	`NCT06128837` - Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer	Phase 3
Terminated	`NCT03406715` - Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)	Phase 2
Withdrawn	`NCT04543916` - Venetoclax and Irinotecan in Relapsed/Refractory SCLC	Phase 1/Phase 2
Recruiting	`NCT05153239` - Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)	Phase 3
Recruiting	`NCT04757779` - A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer	Phase 2